Karyopharm Therapeutics (KPTI) Set to Announce Earnings on Monday

Karyopharm Therapeutics (NASDAQ:KPTI) will likely be issuing its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect Karyopharm Therapeutics to announce earnings of ($0.9460) per share and revenue of $33.54 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 8:00 AM ET.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95). The company had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $32.19 million. On average, analysts expect Karyopharm Therapeutics to post ($4.70) EPS for the current fiscal year and ($2.33) EPS for the next fiscal year.

Karyopharm Therapeutics Stock Down 24.8%

Shares of Karyopharm Therapeutics stock opened at $0.66 on Friday. The firm has a market capitalization of $15.01 million, a P/E ratio of -0.05 and a beta of 1.04. Karyopharm Therapeutics has a 52 week low of $0.31 and a 52 week high of $10.99. The firm’s 50 day moving average is $1.22 and its two-hundred day moving average is $6.02.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Royal Bank Of Canada restated an “outperform” rating and issued a $16.00 target price on shares of Karyopharm Therapeutics in a report on Tuesday, July 21st. Weiss Ratings downgraded shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. HC Wainwright downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research report on Friday, July 31st. Finally, Piper Sandler cut their price target on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

About Karyopharm Therapeutics

Karyopharm Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research centers on selective inhibitors of nuclear export (SINE), a class of compounds designed to interfere with the transport of tumor-suppressing proteins and other molecules in cancer cells.

Karyopharm’s leading product is selinexor, marketed in the United States as XPOVIO and in certain international markets as NEXPOVIO.